Skip to main content

GA Generic Assays GmbH

Company Profile

GA Generic Assays GmbH, established in 2002 by Professor Dr. Dirk Roggenbuck, is an independent family company that focuses primarily on products for the differential diagnosis of autoimmune diseases. Hence, we provide solutions to the challenges faced in this diagnostic field by ensuring optimal product quality and actively engaging in the development of innovative products in new relevant areas.

Located in Ludwig-Erhard-Ring 3, 15827 Dahlewitz, south of Berlin, GA Generic Assays is a continuously growing company in the domestic and international diagnostic markets, with innovation and quality being of prime importance, without neglecting cost-effectiveness. Our new developments are often carried out in cooperation with academic institutions or routine laboratories e.g. Charité Berlin, Dresden University of Technology</a>, </a>Brandenburg University of Technology or with foreign partners.

In 2005, our innovative product, Anti-Ganglioside Dot, for the diagnosis of polyneuropathy, won a technology transfer prize from the Land Brandenburg. In 2010, we were honored by the IHK Potsdam with the Innovation Award for the identification of the main antigen <strong>Glycoprotein 2 (GP2), for the differential diagnosis of class=”yoast-text-mark”>href=”https://www.medipan.de/products-category/crohns-disease-related-products/”>Crohn’s disease.

Our newest development is the ef=”https://www.medipan.de/products-category/cytobead-technology/”>CytoBead® Technology – a revolutionary combination of cell-based immunofluorescence, for screening, and antigen coated microparticles, for differentiation and confirmation of antibody specificity. Through this one-step method of serum testing, in comparison to the currently used two-step process, a completely new organization of the medical laboratory process is made possible.

Together with the sister company, Medipan GmbH, today GA Generic Assays, being active in over 70 countries, is an innovative and world-renowned partner for medical laboratories, physicians, medical institutes and research centres in the manufacture of manual detection test kits and automated systems in the following areas:

ELISA | Radioimmunoassay</span&amp;amp;gt;&lt;/strong>&amp;lt;/a> |=”https://www.medipan.de/products-category/ifa/”> Immunofluorescence assays | Lateral flow | Immunoblot Line & Dot

The target conditions include:

Thyroid diseases | Type 1 diabetes | Rheumatoid arthritis | Polyendocrinopathies | Neuropathies | Vasculitis/Nephritis | Gastroenterology | Autoimmune hepatitis | Anti phospholipid syndrome | Complement system | Progressive systemic sclerosis | Atypical hemolytic-uremic syndrome | Pancreatitis | Systemic rheumatic inflammatory diseases | Celiac diseases | Crohn’s diseases | Myasthenia gravis |

Public funding

Many new developments of GA Generic Assays are supported by public funding. The innovative capabilities of GA Generic Assays can thus be fully exploited and contribute to the growth of the company, especially in recent years.


European Regional Development Fund (EFRE) – Business Development 

Project: As part of the project, GA Generic Assays GmbH is developing specific, quality-assured test kits for autoimmune diagnostics that are optimally tailored to the microscopy system developed by Medipan. The focus is on the development, validation, and production of standardized assays in compliance with international quality requirements.

Objectives and expected results:
The goal is to provide highly sensitive and specific diagnostic test systems which, in combination with the developed device solution, enable reliable and standardized diagnostics. Expected outcomes include improved diagnostic performance parameters, high process stability, and successful integration into a market-ready overall system. The project strengthens the innovative capacity and market position of GA Generic Assays GmbH and contributes to the sustainable development of biotechnological value creation in Brandenburg.

This image features the European Union flag on the left, which consists of a blue background with a circle of twelve yellow stars. To the right of the flag, there is text that reads: "Co-funded by the European Union" in bold blue letters. The overall layout is simple and clear, emphasizing the message of European Union funding support.


GRW Market Development – Participation in Fairs & Congresses

<img class=”alignnone wp-image-9390 ” src=”https://www.medipan.de/wp-content/uploads/2023/12/Ministerium-fur-Wirtschaft-Arbeit-und-Energie.png” alt=”” width=”111″ height=”116″ />

Exhibition Location Date
MEDICA Düsseldorf Novenber 17 – 20, 2025
MedLab Middle East Dubai February 03 – 06, 2025
MEDICA Düsseldorf November 11 – 14, 2024
MedLab Middle East Dubai February 05 – 08, 2024

“yoast-text-mark” /&amp;gt;

/&amp;gt;

Just Transition Fund (JTF) – Business Development

Project: Productive investments by SMEs (de minimis) Expansion of the capacities of an existing production facility


Cooperation

As an innovative technology company, GA Generic Assays places high value on strong national and international networks, as well as close cooperation with industry and academia. This ensures the constant development and improvement of our diagnostic detection methods.

GA Generic Assays GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow OT Dahlewitz, Germany
Tel.: +49 33708 9286 – 0
Fax: +49 33708 4417 – 25
E-Mail: info@genericassays.com
Website: www.genericassays.com
General Manager/CEO: Prof. Dr. Dirk Roggenbuck
Registry Court: Amtsgericht Potsdam Registernummer: HRB 16038 P
VAT identification number: DE 222634510

Notice of Liability

Links

External, direct or indirect links on these webpages to webpages of other providers are given only as a link to the content of third parties; such content is not GA Generic Assays’s own. These links are recognizable from their context, or are explicitly identified as links. GA Generic Assays has no influence whatsoever on the content made available on such third party websites, and does not make this content its own by providing the link. GA Generic Assays is not responsible for third party content or linked webpages in any way.

Referrals

The author is not responsible for any contents linked or referred to from these pages – unless he has full knowledge of illegal contents and would be able to prevent the visitors of his site from viewing those pages. If any damage occurs by the use of information presented there, only the author of the respective pages might be liable, not the one who has linked to these pages. Furthermore the author is not liable for any postings or messages published by users of discussion boards, guest books or mailing lists provided on his page.

Content

The author reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. Parts of the pages or the complete publication might be extended, changed or partly or completely deleted by the author without separate announcement.&lt;/p>

Copyright

The author intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object. The copyright for any material created by the author is reserved. Any duplication or use of objects such as diagrams, sounds or texts in other electronic or printed publications is not permitted without the author’s agreement.

Legal Notice

GA Generic Assays is not liable for the inability to access these webpages, the quality of access, the quality of reproduction of the webpages, for memory breakdown, viruses or other harmful code, disruptions of service, possible delays, errors, failures, or faulty transmissions.

The content made available by GA Generic Assays on these webpages is protected by copyright. The user may use and make copies (e.g. by printout) of parts of the content exclusively for private, non-commercial purposes.

Payment and Delivery Terms

All prices are in EURO (€) only. GA Generic Assays GmbH will deliver EX WORKS.

Payment terms are prepayment (payment in advance) unlike other written agreements.

Insurance, handling and shipping costs are not included. So transport costs have to be added to the invoice. Your own courier accounts may be accepted.

If any consignment should be damaged during transport, the buyer will be responsible to collect the claims from the forwarding agent, the transport company or the insurance company.

All fees, duties, taxes and other charges occurring with the sales and use of the purchased goods are to the expense of the buyer. The total price including all above mentioned additional costs are payable to:

table {
width: 100%;
border-collapse: collapse;
}
th, td {
padding: 8px;
text-align: left;
}
Bank Deutsche Bank AG Sparkasse Oder-Spree
City, ZIP code Berlin, 14169 Frankfurt (Oder), 15230
Street Teltower Damm 2 Franz-Mehring Str. 22
Country Germany Germany
BIC (SWIFT) DEUTDEBB101 WELA DED1LOS
IBAN DE73 1007 0100 0300 0320 00 DE58 1705 5050 1101 6294 16
VAT DE222634510 DE222634510

Please mention the invoice number you refer to during payment.

General Terms and Conditions

Contact us